Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of 3DCRT/IMRT with S-1 in elderly patients with locally advanced esophageal squamous cell carcinoma
ChiCTR1900020876Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tegafur in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoints: tumor size, survival rate and 3 more. Planned start Feb 2019; status: not yet recruiting.
02
Drugs
tegafur
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR1900020876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900020876.